Lectin-like oxidized LDL receptor-1 is a cell-adhesion molecule involved in endotoxin-induced inflammation

Honjo, Megumi; Nakamura, Kayo; Yamashiro, Kenji; Kiryu, Junichi; Tanihara, Hidenobu; McEvoy, Leslie M.; Honda, Yoshio; Butcher, Eugene C.; Masaki, Τοmoh; Sawamura, Tatsuya

doi:10.1073/pnas.0337528100

Cited by 139 publications

(117 citation statements)

References 34 publications

Supporting

Mentioning

112

Contrasting

Order By: Relevance

“…It functions as a cell-adhesion molecule mediating the platelet-endothelium interaction and is involved in endotoxin-induced inflammation that may initiate and promote atherosclerosis Honjo et al 2003). LOX-1 also supports adhesion of mononuclear leukocytes or monocyte-like THP-1 cells under either static or flow conditions (Hayashida et al 2002).…”

Section: Effects Related To Atherosclerosismentioning

confidence: 99%

Lectin‐like Oxidized Low‐density Lipoprotein Receptor‐1, a New Promising Target for the Therapy of Atherosclerosis?

Chen

Zhang

2007

Cardiovascular Drug Reviews

View full text Add to dashboard Cite

Endothelial activation and dysfunction induced by oxidized modified low-density lipoprotein (ox-LDL) is one of the key steps in the initiation of atherosclerosis. Recent studies have shown that a new lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) mediates the recognition and internalization of ox-LDL. LOX-1 is the main receptor for ox-LDL and may play an important role in the pathogenesis of hypertension, diabetes, and, especially, of atherosclerosis. The potential role of LOX-1 in the pathogenesis of atherosclerosis includes: endocytosis of ox-LDL, expression co-location with atherosclerosis enhanced by atherosclerosis-related risk factors, elevated LOX-1 protein in cardiovascular disease, effects related to atherosclerosis and eliminated by antiatherosclerotic drugs. Identification and regulation of LOX-1 and understanding its signal transduction pathways might improve our insight toward the pathogenesis of atherosclerosis and provide a selective treatment approach. LOX-1 might be a potential and promising target for the development of novel antiatherosclerotic drugs. However, due to limited knowledge about LOX-1, there are still many questions to be answered.

show abstract

Section: Effects Related To Atherosclerosismentioning

confidence: 99%

Lectin‐like Oxidized Low‐density Lipoprotein Receptor‐1, a New Promising Target for the Therapy of Atherosclerosis?

Chen

Zhang

2007

Cardiovascular Drug Reviews

View full text Add to dashboard Cite

show abstract

“…8 In addition to being the main receptor for oxLDL, LOX-1 has the ability to bind damaged or apoptotic cells, activated platelets, advanced glycation end products, and pathogenic organisms. [13][14][15] Once bound, these ligands can be endocytosed or phagocytosed into the cell. Under physiological conditions, LOX-1 may play a role in host defense or serve to scavenge cellular debris.…”

Section: Novel Inflammatory Mediators Of Inflammation and Endothelialmentioning

confidence: 99%

Biomarkers of Vascular Disease Linking Inflammation to Endothelial Activation

et al. 2003

View full text Add to dashboard Cite

A therosclerosis is regarded as a dynamic and progressive disease arising from the combination of endothelial dysfunction and inflammation. [1][2][3][4][5][6] This article is the second in a 2-part series examining emerging markers of inflammation and endothelial cell activation. The first article 7 provided a brief overview of the link between inflammation, endothelial dysfunction, and atherosclerosis and began the examination of emerging inflammatory mediators. This second article continues with an exploration of more novel markers for cardiovascular disease.

show abstract

“…Deletion of LOX-1 in mice preserves endothelial function, leading to reduction in atherogenesis (20 ). In addition to oxidized LDL, LOX-1 binds various ligands, e.g., apoptotic cells, activated platelets, leukocytes, and bacteria (21)(22)(23)(24)(25). Related functions of LOX-1 include involvement in inflammation, myocardial infarction, and intimal thickening after balloon catheter injury (23, 26 -29 ).…”

mentioning

confidence: 99%

Oxidized LDL Receptor LOX-1 Binds to C-Reactive Protein and Mediates Its Vascular Effects

et al. 2009

Self Cite

View full text Add to dashboard Cite

Background: C-reactive protein (CRP) exerts biological activity on vascular endothelial cells. This activity may promote atherothrombosis, but the effects of this activity are still controversial. Lectin-like oxidized LDL receptor-1 (LOX-1), the oxidized LDL receptor on endothelial cells, is involved in endothelial dysfunction induced by oxidized LDL. methods: We used laser confocal microscopy to examine and fluorescence cell image analysis to quantify the binding of fluorescently labeled CRP to cells expressing LOX-1. We then examined the binding of unlabeled CRP to recombinant human LOX-1 in a cell-free system. Small interfering RNAs (siRNAs) against LOX-1 were applied to cultured bovine endothelial cells to analyze the role of LOX-1 in native cells. To observe its in vivo effects, we injected CRP intradermally in stroke-prone spontaneously hypertensive (SHR-SP) rats and analyzed vascular permeability. results: CRP bound to LOX-1–expressing cells in parallel with the induction of LOX-1 expression. CRP dose-dependently bound to the cell line and recombinant LOX-1, with significant binding detected at 0.3 mg/L CRP concentration. The Kd value of the binding was calculated to be 1.6 × 10–7 mol/L. siRNA against LOX-1 significantly inhibited the binding of fluorescently labeled CRP to the endothelial cells, whereas control RNA did not. In vivo, intradermal injection of CRP-induced vascular exudation of Evans blue dye in SHR-SP rats, in which expression of LOX-1 is greatly enhanced. Anti–LOX-1 antibody significantly suppressed vascular permeability. Conclusions: CRP and oxidized LDL-receptor LOX-1 directly interact with each other. Two risk factors for ischemic heart diseases, CRP and oxidized LDL, share a common molecule, LOX-1, as their receptor.

show abstract

Lectin-like oxidized LDL receptor-1 is a cell-adhesion molecule involved in endotoxin-induced inflammation

Cited by 139 publications

References 34 publications

Lectin‐like Oxidized Low‐density Lipoprotein Receptor‐1, a New Promising Target for the Therapy of Atherosclerosis?

Lectin‐like Oxidized Low‐density Lipoprotein Receptor‐1, a New Promising Target for the Therapy of Atherosclerosis?

Biomarkers of Vascular Disease Linking Inflammation to Endothelial Activation

Oxidized LDL Receptor LOX-1 Binds to C-Reactive Protein and Mediates Its Vascular Effects

Contact Info

Product

Resources

About